Biopharmaceutical News and Research

RSS

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

Quality Control in Food and Beverage Production

In this interview, News-Medical Life Sciences talks to Angela Visgandis, Product Specialist at Thermo Fisher Scientific about how quality control in the food and beverage industry has changed over the years.

From Thermo Fisher Scientific – Laboratory Products Division – Food & Beverage Quality Control 11 Aug 2022

New compound proves to be potent against more than 300 drug-resistant bacteria

Urinary tract infections are common, yet are increasingly tough to treat because the bacteria that cause them are becoming resistant to many antibiotics.

10 Aug 2022

Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery

In this interview, we speak to Tom Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product and the future of drug discovery.

From CN-Bio 3 Aug 2022

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval

Recently, ACROBiosystems won Cite Awards, being titled "the Winner of Protein Supplier to Watch in 2022".

From ACROBiosystems 1 Aug 2022

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

The International Vaccine Institute (IVI) successfully completed the '2022 Introductory Course for Biologics Development and Manufacturing' on July 29 to train 106 participants from 24 low- and middle-income countries (LMICs) and 32 from the Republic of Korea.

29 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Novel technique could offer an improved route to drug discovery and development

A new technique that can analyze how drug molecules bind to proteins in tissue samples could offer an improved route to drug discovery and development.

14 Jul 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

From Curia 9 Jun 2022

Misinformation clouds America’s most popular emergency contraception

A brand of specialty mozzarella cheeses. A collection of natural-gas storage terminals. And America’s top-selling emergency contraception.

7 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

MD Anderson and National Resilience launch the Cell Therapy Manufacturing Center

The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.

2 Jun 2022

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

When Case Western Reserve University research showed that artificial intelligence (AI) could identify which lung cancer patients would benefit from chemotherapy, a national magazine called the finding one of the "10 Most Incredible Medical Breakthroughs of 2018."

25 May 2022

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

Landmark $20 million gift received to establish Mount Sinai-Royalty Pharma Alliance for Health Equity Research

Marking a major advance in its efforts to achieve equity in the delivery of health care, the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) announced today that its Institute for Health Equity Research (IHER) has received a landmark $20 million gift over four years from Royalty Pharma plc and certain members of its management team.

16 May 2022

New therapeutic approach for cardiac repair after a heart attack

Following a heart attack, the human body is incapable of repairing lost tissue due to the heart's inability to generate new muscle.

12 May 2022

Sphere Fluidics strengthens commercial team with three new senior hires

Key appointments form part of broader ongoing recruitment plans to support expanded operations and product development.

From Sphere Fluidics 10 May 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022